NanoEcho (NANECH) investor relations material

Executive summary

• Achieved first commercial system sale, generating initial revenues and validating operational capabilities.

• Continued clinical validation of diagnostic system, with focus on proof-of-concept studies and system improvements.

• Maintained high activity despite financial constraints, implementing targeted cost savings and efficiency measures.

• Patent portfolio strengthened with new US design patent approval.

Financial highlights

• Q2 2026 net sales reached 488 TSEK, compared to 0 TSEK in Q2 2025, driven by first system sale.

• Net loss after tax for Q2 2026 was -3,499 TSEK, improved from -4,512 TSEK in Q2 2025.

• Cash flow from operations for Q2 2026 was -3,613 TSEK, compared to -3,817 TSEK in Q2 2025.

• Cash and cash equivalents at period end were 533 TSEK, down from 8,672 TSEK a year earlier.

• Equity at period end was 14,138 TSEK, with a solid equity ratio of 79%.

Outlook and guidance

• Focus remains on clinical validation, market approval, and commercialization, with plans to submit for market approval by 2029, contingent on securing necessary capital.

• Short-term and long-term financial situation remains strained; ongoing efforts to secure bridge and long-term financing.

• Updated EIC Accelerator grant application submitted, with next evaluation step in September.